Product Reports Resources Pricing Login Book a demo

Cyted

Biotech & Life Sciences · Cambridge, United Kingdom · Founded 2020

Unique approach combines expertise in gastrointestinal oncology, digital pathology and AI-driven biomarker discovery MoreLess

Cyted.ai is a pioneering company in the field of digital diagnostics, focusing on gastrointestinal oncology. The company leverages advanced technologies such as artificial intelligence (AI) and digital pathology to develop innovative diagnostic solutions. Cyted.ai primarily serves public and private healthcare providers, offering histopathology services, which involve the microscopic examination of tissue samples to detect diseases.

The company operates in the healthcare market, specifically targeting the early detection and monitoring of esophageal cancer and other gastrointestinal diseases. This is a critical area, as over 5 million people are diagnosed with digestive system cancers annually, with esophageal cancer being one of the deadliest due to its poor survival rates and late-stage detection.

Cyted.ai's business model revolves around providing a fast and simple test for esophageal health. This test aims to detect and monitor signs of pre-cancer and other diseases, thereby enabling earlier and less invasive diagnostics compared to traditional methods like endoscopy. By offering these advanced diagnostic services, Cyted.ai helps healthcare providers improve patient outcomes and reduce the mortality rate associated with late-stage cancer diagnoses.

The company generates revenue by offering its histopathology services to healthcare providers on a fee-for-service basis. Additionally, Cyted.ai's unique clinical pathway and data platform allow it to scale its pathology data, providing valuable insights that can further enhance patient care and streamline diagnostic processes.

In summary, Cyted.ai is transforming the healthcare landscape by providing cutting-edge diagnostic solutions that enable earlier detection and better management of gastrointestinal diseases. This not only improves patient outcomes but also addresses a significant bottleneck in the current diagnostic process.

Keywords: Digital Diagnostics, AI, Gastrointestinal Oncology, Histopathology, Esophageal Cancer, Early Detection, Healthcare Providers, Data Platform, Patient Care, Innovative Solutions.

Valuation $100–500M
Revenue $1–10M
Headcount <100
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Cyted and the history behind them.

Company overview

Cyted company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2020
Headquarters
Cambridge, United Kingdom
Employees
73
Open positions
None listed
Dealroom signal
85.9
client focusb2btechnologyArtificial IntelligencetechnologyDeep Techsub industryBioTechnologysub industryHealth Platformbusiness modelSaaSindustryHealthsectorBiotechnologysectorOncologysectorCore AIsectorPrecision MedicinesectorHealth DiagnosticssectorSpinoutsectorClinical Decision Support

Valuation & funding

Cyted funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Sep 2025 $6M British Business Bank
SERIES BOther financing Sep 2025 $38M $152M Business Growth Fund · Morningside · EQT Life Sciences · Advent Life Sciences
FundingOther financing May 2024 $0 MedTech Innovator
GRANTOther financing Dec 2023 $1.3M Undisclosed
EARLY VCOther financing May 2023 $13M $53M Business Growth Fund · Morningside
GRANTOther financing May 2023 SBRI Healthcare
EARLY VCOther financing Feb 2022 Undisclosed
GRANTOther financing Aug 2021 SBRI Healthcare
GRANTOther financing Feb 2020 Morningside
EARLY VCOther financing Feb 2020 Morningside
Showing 10 recorded eventsUnlock the complete deal history →

Financials

Revenue and workforce over time

Available revenue and workforce history. Fields without reported data are omitted.

YearRevenueGrowthEmployees
2026 $8M 0% 73
2025 $8M 0% 65
2024 $8M 0% 57
2023 $8M +16.3% 72
2022 $6.9M +154.8% 61
2021 $2.7M 33
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Cyted website traffic

Latest recorded traffic for Cyted is 2.2K monthly website visits, up 423.8% over the last three months. Cyted's team grew 12.3% over the past year.

Latest monthly visits2.2K 3-month web change+423.8% 1-year team growth+12.3%
Monthly website visits44 observations · Aug 2020–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Cyted compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Cyted's talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Cyted's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Morningside
SBRI Healthcare
Series A 3 investors entered at this stage
Business Growth Fund
EQT Life Sciences
Advent Life Sciences
Series B+ 1 investor entered at this stage
British Business Bank
Other known 2 additional known investors
MedTech Innovator
University of Cambridge

Global footprint

Where Cyted has talent and traffic

Workforce by country
3 countries with
team presence
🇬🇧 United Kingdom82%
🇺🇸 United States14%
🇦🇷 Argentina2%
3 countries shown

In the news

Latest news about Cyted

Recent press, funding announcements, and product moves mentioning Cyted — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Cyted

An AI-synthesized read of the highest-engagement posts about Cyted on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cyted’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.